Modular Medical, Inc. Files 8-K with Material Agreement

TL;DR

Modular Medical signed a big deal, filed financials. Big news incoming.

AI Summary

On December 10, 2025, Modular Medical, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. The filing was made on December 11, 2025.

Why It Matters

This 8-K filing indicates a significant development for Modular Medical, Inc., likely involving a new contract or partnership that could impact its business operations and financial future.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the specifics of this agreement are not detailed in the provided summary, requiring further investigation.

Key Players & Entities

• Modular Medical, Inc. (company) — Registrant
• December 10, 2025 (date) — Earliest event reported
• December 11, 2025 (date) — Filing date
• Nevada (jurisdiction) — State of incorporation
• San Diego, California (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — f the Company's common stock, par value $0.001 per share (the "Common Stock"), referre
• $4.68 m — from the Offering will be approximately $4.68 million, before deducting underwriting di
• $85,000 — on with the Offering in an amount up to $85,000. Each two shares of Common Stock are
• $0 — mpanying warrant at a combined price of $0.77, yielding an effective price of $0.3
• $0.38 — f $0.77, yielding an effective price of $0.38 per share and $0.01 per warrant. The Wa
• $0.01 — effective price of $0.38 per share and $0.01 per warrant. The Warrants will have an
• $0.45 — Warrants will have an exercise price of $0.45 per share (the "Exercise Price"), are e

Filing Documents

• ea0269264-8k_modular.htm (8-K) — 34KB
• ea026926401ex1-1_modular.htm (EX-1.1) — 306KB
• ea026926401ex4-1_modular.htm (EX-4.1) — 100KB
• ea026926401ex4-2_modular.htm (EX-4.2) — 105KB
• ea026926401ex5-1_modular.htm (EX-5.1) — 8KB
• ea026926401ex99-1_modular.htm (EX-99.1) — 9KB
• ea026926401ex99-2_modular.htm (EX-99.2) — 11KB
• ex5-1_001.jpg (GRAPHIC) — 5KB
• ex99-1_001.jpg (GRAPHIC) — 10KB
• ex99-2_001.jpg (GRAPHIC) — 10KB
• 0001213900-25-120759.txt ( ) — 905KB
• modd-20251210.xsd (EX-101.SCH) — 3KB
• modd-20251210_lab.xml (EX-101.LAB) — 33KB
• modd-20251210_pre.xml (EX-101.PRE) — 22KB
• ea0269264-8k_modular_htm.xml (XML) — 3KB

01 Entry into

Item 1.01 Entry into a Material Definitive Agreement. On December 10, 2025, Modular Medical, Inc. (the "Company") entered into an Underwriting Agreement (the "Agreement") with Newbridge Securities Corporation (the "Underwriter"), relating to a firm commitment underwritten offering (the "Offering") of (i) 12,173,000 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), referred to as the "Firm Shares," and (ii) accompanying warrants exercisable to purchase up to 6,086,500 shares of Common Stock (the "Warrants"), referred to as the "Firm Warrants." The gross proceeds to the Company from the Offering will be approximately $4.68 million, before deducting underwriting discounts and commissions and offering expenses. Pursuant to the Agreement, the Company agreed to pay the Underwriter a cash fee equal to 7% of the gross proceeds received from the Offering and to reimburse the Underwriter for its expenses incurred in connection with the Offering in an amount up to $85,000. Each two shares of Common Stock are being offered and sold together with one accompanying warrant at a combined price of $0.77, yielding an effective price of $0.38 per share and $0.01 per warrant. The Warrants will have an exercise price of $0.45 per share (the "Exercise Price"), are exercisable immediately upon issuance, and will expire five years following the date of issuance. The Warrants will be issued pursuant to a warrant agency agreement to be entered into by and between the Company and Colonial Stock Transfer Company, Inc., as warrant agent. The Offering closed on December 11, 2025 (the "Closing Date"). The Offering was made pursuant to an effective registration statement on Form S-3 (Registration Statement No. 333- 287313) previously filed with the Securities and Exchange Commission (the "SEC") on May 15, 2025 and declared effective by the SEC on May 22, 2025, and a preliminary prospectus supplement relating to the Offering dated December 9, 2025 and a f

01 Other Events

Item 8.01 Other Events. The Company issued press releases announcing the launch of the Offering on December 9, 2025 and the pricing of the Offering on December 10, 2025. Copies of these press releases are attached hereto as Exhibits 99.1 and 99.2 and are each incorporated herein by reference. 1

01 Financial

Item 9.01 Financial (d) Exhibits The following exhibits are filed with this report: Exhibit Number Exhibit Description 1.1 Underwriting Agreement, dated as of December 10, 2025, between the Company and Newbridge Securities Corporation 4.1 Form of Warrant 4.2 Form of Underwriter Warrant 5.1 Opinion of Lucosky Brookman, LLP 23.1 Consent of Lucosky Brookman, LLP (included in Exhibit 5.1) 99.1 Press Release dated December 9, 2025, regarding the launch of the Offering 99.2 Press Release dated December 10, 2025, regarding the pricing of the Offering 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MODULAR MEDICAL, INC. Date: December 11, 2025 By: /s/ James E. Besser James E. Besser Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR